Physician profile
Johnson Mwangi
NPI 1578748505
$4,772.48
in general payments reported to CMS, 2019-2025
22 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $1,252 · 2024: $1,412 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,047 · Education: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,047.03 |
| Education | $489.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $833.23 | 2023-2025 | |
| Abbvie INC. | $832.74 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $400.57 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $364.71 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $350.87 | 2023-2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $291.98 | 2023-2025 | |
| Pfizer INC. | $234.58 | 2022-2025 | |
| Silk Road Medical, INC. | $223.99 | 2022 | |
| Janssen Biotech, INC. | $214.60 | 2023-2024 | Tremfya |
| Dermavant Sciences, INC. | $177.98 | 2024 | Vtama |
| Leo Pharma INC. | $142.76 | 2023-2025 | Adbry |
| Ucb, INC. | $107.34 | 2025 | Bimzelx |
| Incyte Corporation | $90.69 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $81.20 | 2023-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $73.39 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $66.50 | 2024 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $64.81 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $61.43 | 2024-2025 | Zoryve |
| Amgen INC. | $59.89 | 2023-2025 | Otezla, Otezla |
| Almirall LLC | $45.39 | 2023-2025 | Seysara |
| Convatec INC. | $37.22 | 2025 | |
| Journey Medical Corporation | $16.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnson Mwangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.